波美拉尼亚健康研究中的同型精氨酸、ADMA 和 SDMA 的血清参考区间。

Serum reference intervals of homoarginine, ADMA, and SDMA in the study of health in Pomerania.

出版信息

Clin Chem Lab Med. 2014 Dec;52(12):1835-42. doi: 10.1515/cclm-2014-0314.

DOI:10.1515/cclm-2014-0314

Abstract

BACKGROUND

Low circulating homoarginine as well as high levels of asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA) have been associated with impaired cardiovascular (CV) outcome and mortality in patients at risk and in the general population. The present study aimed to formulate reference intervals for serum homoarginine, ADMA, and SDMA to improve risk stratification between healthy individuals and individuals at risk.

METHODS

We determined age- and sex-specific reference intervals for homoarginine, ADMA, and SDMA in a subgroup of 1359 healthy participants (no diabetes mellitus, CV disease, increased blood pressure, elevated blood lipids, chronic kidney disease stadium III or IV, or a body mass index >30) of the Study of Health in Pomerania (SHIP) using quantile regression analyses. Homoarginine, ADMA, and SDMA serum concentrations were measured using liquid chromatography-tandem mass spectrometry.

RESULTS

Median age of the investigated cohort was 36 (25th; 75th percentile 28; 47) years, with 62% women. Median serum concentrations of homoarginine, ADMA, and SDMA were 2.63 (2.08; 3.32) μmol/L, 0.64 (0.57; 0.73) μmol/L, and 0.43 (0.37; 0.49) μmol/L, respectively. Serum levels of homoarginine, ADMA, and SDMA showed material age- and sex-related differences (p<0.05 for all). Overall reference ranges were 1.41-5.00 and 1.20-5.53 μmol/L (2.5th; 97.5th percentile; for men and women, respectively) for homoarginine, 0.41-0.95 and 0.43-0.96 μmol/L for ADMA, and 0.30-0.67 and 0.27-0.63 μmol/L for SDMA.

CONCLUSIONS

We formulated for the first time homoarginine, ADMA, and SDMA reference intervals in serum. These reference intervals might be useful for individual CV risk stratification.

摘要

背景

低循环同型精氨酸以及高不对称二甲基精氨酸（ADMA）和对称二甲基精氨酸（SDMA）与心血管（CV）风险患者和普通人群的心血管预后和死亡率受损有关。本研究旨在制定血清同型精氨酸、ADMA 和 SDMA 的参考区间，以改善健康个体和高危个体之间的风险分层。

方法

我们使用定量回归分析确定了 Study of Health in Pomerania（SHIP）中 1359 名健康参与者（无糖尿病、心血管疾病、高血压、血脂升高、慢性肾脏病 3 或 4 期或身体质量指数>30）的同型精氨酸、ADMA 和 SDMA 的年龄和性别特异性参考区间。使用液相色谱-串联质谱法测量同型精氨酸、ADMA 和 SDMA 的血清浓度。

结果

所调查队列的中位年龄为 36 岁（25 百分位；75 百分位 28；47），女性占 62%。同型精氨酸、ADMA 和 SDMA 的血清浓度中位数分别为 2.63（2.08；3.32）μmol/L、0.64（0.57；0.73）μmol/L 和 0.43（0.37；0.49）μmol/L。同型精氨酸、ADMA 和 SDMA 的血清水平存在明显的年龄和性别差异（所有 p<0.05）。总体参考范围分别为 1.41-5.00 和 1.20-5.53 μmol/L（2.5 百分位；97.5 百分位；男性和女性），同型精氨酸为 0.41-0.95 和 0.43-0.96 μmol/L，ADMA 为 0.30-0.67 和 0.27-0.63 μmol/L，SDMA。